Oral mercaptopurine in childhood leukemia: influence of food intake on bioavailability.

Plasma concentrations of 6-mercaptopurine (6-MP) were determined by gas chromatography-mass spectrometry. Ten children (nine with acute lymphatic leukemia) were studied on 2 consecutive days after oral intake of 6-MP. On one day the drug was administered in the fasting state and on the other (in random order) together with breakfast. The peak plasma concentrations of 6-MP after the dose intake with breakfast in percent of that in the fasting state (meal in % of fasting for each individual) varied between 33 and 181% (mean 111), and the area under the plasma concentration-time curve varied between 47 and 186% (mean 103). Thus, there were considerable variations among patients, but, for the group as a whole, there were no statistically significant differences between the two experimental conditions. This study cannot therefore form the basis for a recommendation as to whether 6-MP should be administered on an empty stomach or together with food.

[1]  Mark L. Greenberg,et al.  Pharmacokinetic determinants of 6‐mercaptopurine myelotoxicity and therapeutic failure in children with acute lymphoblastic leukemia , 1986, Clinical pharmacology and therapeutics.

[2]  C. Peterson,et al.  Large Interindividual Variations in the Pharmacokinetics of Oral 6‐Mercaptopurine in Maintenance Therapy of Children with Acute Leukaemia and Non‐Hodgkin Lymphoma , 1986, Acta paediatrica Scandinavica.

[3]  J. Lilleyman,et al.  Oral 6‐mercaptopurine in childhood leukemia: Parent drug pharmacokinetics and active metabolite concentrations , 1986, Clinical pharmacology and therapeutics.

[4]  J. Ludvigsson,et al.  Plasma and erythrocyte concentrations of mercaptopurine after oral administration in children. , 1986, Pediatric hematology and oncology.

[5]  F. Balis,et al.  Influence of food intake on bioavailability of oral 6-mercaptopurine in children with acute lymphoblastic leukemia. , 1986, Pediatric hematology and oncology.

[6]  S. Sallan,et al.  Comparative analysis of treatment programs for childhood acute lymphoblastic leukemia. , 1985, Seminars in oncology.

[7]  R. Riccardi,et al.  Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? , 1983, The New England journal of medicine.

[8]  P. Hartvig,et al.  Extractive alkylation of 6-mercaptopurine and determination in plasma by gas chromatography-mass spectrometry. , 1981, Journal of chromatography.

[9]  C. R. Pinkerton,et al.  CAN FOOD INFLUENCE THE ABSORPTION OF METHOTREXATE IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKÆMIA? , 1980, The Lancet.

[10]  A. Mauer Therapy of Acute Lymphoblastic Leukemia in Childhood , 1980 .